BriaCell Therapeutics EBIT

The latest EBIT for BCTXL is $-26M as of April 2026. That compares with $-24M in the prior-year period — down 7.5% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside BriaCell Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, BCTXL's EBIT moved from $-24M to $-26M — a 7.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in BriaCell Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, BCTXL currently prints $-26M for EBIT, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at BriaCell Therapeutics's growth, margins, and balance sheet.

A EBIT figure of $-26M for BCTXL is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting BCTXL's EBIT ($-26M), review year-over-year change from $-24M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.